PVLA News

Form 8-K

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference

Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference